Search

Your search keyword '"Vanesa Gregorc"' showing total 2 results
Start Over Author "Vanesa Gregorc" Journal critical reviews in oncology/hematology
2 results on '"Vanesa Gregorc"'

1. Role of stereotactic radiosurgery for the treatment of brain metastasis in the era of immunotherapy: A systematic review on current evidences and predicting factors

Author

Francesca Roncelli, Filippo Gagliardi, Vanesa Gregorc, Alessandra Bulotta, Stefano Cascinu, Pierfrancesco De Domenico, Lina Raffaella Barzaghi, Silvia Snider, Pietro Mortini, Chiara Lazzari, Edoardo Pompeo, G. Finocchiaro, Gagliardi, Filippo, De Domenico, Pierfrancesco, Snider, Silvia, Roncelli, Francesca, Pompeo, Edoardo, Barzaghi, Lina Raffaella, Bulotta, Alessandra, Gregorc, Vanesa, Lazzari, Chiara, Cascinu, Stefano, Finocchiaro, Gaetano, and Mortini, Pietro

Subjects
Oncology, medicine.medical_specialty, Lung Neoplasms, medicine.medical_treatment, NSCLC, Radiosurgery, Combined treatment, Internal medicine, Carcinoma, Non-Small-Cell Lung, parasitic diseases, Medicine, Humans, In patient, Stereotactic radiosurgery, Melanoma, Retrospective Studies, business.industry, Brain Neoplasms, Brain metastasis, Hematology, Immunotherapy, medicine.disease, Radiological weapon, Non small cell, business
Abstract

Stereotactic radiosurgery (SRS) in combination with immunotherapy (IT) is increasingly used in the setting of melanoma and non-small cell lung cancer (NSCLC) brain metastases (BM). The synergistic properties of this treatment combination are still not deeply understood. IT-SRS appropriate combination has been envisioned as a strategic point in patients' management. Authors performed a systematic review on current evidences up to December 2020. The impact of SRS-IT and different IT schedules on survival, local/distant intracranial control and toxicity, as well as predictive factors for relevant oncological and radiological outcomes has been analyzed. Authors retrieved 23 pertinent studies. Combining SRS with IT resulted in a significant improvement in OS and lesion response with no increase in radionecrosis, hemorrhage or other complications. The present review suggests that combining IT to SRS is safe and effective in providing a significant improvement in relevant clinical and radiological outcomes in melanoma and NSCLC BMs patients.

Published
2021

2. New perspectives in the second-line treatment of non squamous NSCLC patients: Results from a large Italian Lung Cancer Working Group

Author

Alessandro Morabito, Anna Manzo, Vanesa Gregorc, Maria Ida Abate, Diego Cortinovis, Umberto Malapelle, Maria Rita Migliorino, Cortinovis, Diego, Gregorc, Vanesa, Migliorino, Maria Rita, Abate, Maria Ida, Manzo, Anna, Malapelle, Umberto, and Morabito, Alessandro

Subjects
Oncology, medicine.medical_specialty, Indoles, Lung Neoplasms, Nintedanib, Second line therapy, Docetaxel, Pembrolizumab, Antibodies, Monoclonal, Humanized, Ramucirumab, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Atezolizumab, Carcinoma, Non-Small-Cell Lung, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, 030212 general & internal medicine, Lung cancer, Randomized Controlled Trials as Topic, Antineoplastic Combined Chemotherapy Protocol, business.industry, Non squamous NSCLC, Antibodies, Monoclonal, Cancer, Hematology, medicine.disease, Lung Neoplasm, Nivolumab, Italy, chemistry, Indole, 030220 oncology & carcinogenesis, Therapeutic strategy, Taxoids, business, Human, medicine.drug
Abstract

Lung cancer is still considered a big killer among cancer diseases, due to high incidence and mortality rates. The newer frontiers of therapeutic development regard the discovery of oncogene driven tumours: however, the majority of NSCLC patients are wild type and they cannot be treated with targeted based agents. The recent positive results obtained with immunotherapy and with the combination of angiogenesis inhibitors and docetaxel, changed the therapeutic scenario of the second line therapy of non squamous NSCLC without actionable mutations. A major issue is currently the lack of predictive biomarkers that could help the oncologists in the choice of the best second-line treatment. Aim of this project was to define an optimal therapeutic pathway for patients with non-squamous NSCLC, through a working group of a large number of Italian lung cancer oncologists. Panellists have identified and discussed the more significant criteria in the second-line setting for a therapeutic decision between the combination of angiogenesis inhibitors plus chemotherapy or immunotherapy. Finally, they expressed their preference on each criterion, building a proposal of a decision-making tree for a second-line treatment of non-squamous NSCLC.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results